{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:05:19Z","timestamp":1792699519724,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Key Project for Graduate Students of the Jiangxi Society of Science Education","award":["2025KXJYS142"],"award-info":[{"award-number":["2025KXJYS142"]}]},{"name":"The Natural Science Foundation of Jiangxi Province","award":["20252BAC200519"],"award-info":[{"award-number":["20252BAC200519"]}]},{"name":"The Natural Science Foundation of Jiangxi Province","award":["20252BAC250124"],"award-info":[{"award-number":["20252BAC250124"]}]},{"name":"The National Natural Science Foundation Incubation Program of the Second Affiliated Hospital of Nanchang University","award":["2025YNFY12035"],"award-info":[{"award-number":["2025YNFY12035"]}]},{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82460609"],"award-info":[{"award-number":["82460609"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acquired resistance remains a major obstacle in molecular-targeted therapy for advanced hepatocellular carcinoma (HCC). This study aimed to elucidate the role and underlying mechanisms of SERPINE2 in mediating lenvatinib resistance by suppressing ferroptosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed SERPINE2 expression and its clinical prognostic relevance using public databases (TCGA) and clinical samples (tumor tissues and serum) from patients with HCC treated with lenvatinib. By establishing hypoxic and acquired lenvatinib-resistant HCC cell models, combined with subcutaneous xenograft and orthotopic liver cancer mouse models, we systematically evaluated the functional role of SERPINE2 in tumor proliferation, apoptosis, ferroptosis, and lenvatinib resistance in vitro and in vivo. Mechanistic insights were obtained through transcriptome sequencing (RNA-seq), quantitative proteomics, co-immunoprecipitation (Co-IP), nuclear-cytoplasmic fractionation, and measurement of key ferroptosis indicators (lipid ROS, mitochondrial membrane potential, and transmission electron microscopy). Finally, we assessed the therapeutic potential of targeted interventions combining a JAK inhibitor (Ruxolitinib) or NRF2 inhibitor (ML385) with lenvatinib to overcome resistance in vitro and in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>SERPINE2 was markedly upregulated in hypoxic and lenvatinib-resistant HCC models and clinical tissues, correlating with a poor prognosis. Mechanistically, SERPINE2 activates the JAK2\/STAT3 signaling pathway, promotes the STAT3-NRF2 interaction, and facilitates NRF2 nuclear translocation. This upregulates the antioxidant enzyme GCLC, which strengthens glutathione synthesis, inhibits lipid peroxidation and ferroptosis, and ultimately confers lenvatinib resistance. Inhibiting SERPINE2, STAT3, or GCLC restored ferroptosis and re-sensitized HCC cells to lenvatinib. Furthermore, the combination treatments exhibited significant synergistic antitumor effects in vitro and in vivo. Clinically, elevated SERPINE2 levels positively correlated with GCLC, predicted worse survival outcomes, and effectively distinguished lenvatinib-resistant patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study established the SERPINE2\u2013JAK2\/STAT3\u2013NRF2\u2013GCLC signaling axis as a key mechanism driving ferroptosis resistance and lenvatinib treatment failure. Targeting this axis provides a novel therapeutic strategy for overcoming lenvatinib resistance in HCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03746-y","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T09:15:16Z","timestamp":1780737316000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["SERPINE2-mediated activation of JAK2\/STAT3 facilitates NRF2 nuclear translocation and GCLC transcription to confer ferroptosis resistance and lenvatinib resistance in hepatocellular carcinoma"],"prefix":"10.1186","volume":"45","author":[{"given":"Kan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongkang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinwen","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"3746_CR1","doi-asserted-by":"crossref","unstructured":"Filho AM, Laversanne M, Ferlay J, Colombet M, Pi\u00f1eros M, Znaor A, et al. The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide. International journal of cancer. 2025;156(7):1336\u201346.","DOI":"10.1002\/ijc.35278"},{"key":"3746_CR2","doi-asserted-by":"crossref","unstructured":"Reig M, Sanduzzi-Zamparelli M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, et al. BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update. Journal of hepatology. 2026;84(3):631\u201354.","DOI":"10.1016\/j.jhep.2025.10.020"},{"issue":"9","key":"3746_CR3","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1111\/liv.12818","volume":"35","author":"JW Park","year":"2015","unstructured":"Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver international: official J Int Association Study Liver. 2015;35(9):2155\u201366.","journal-title":"Liver international: official J Int Association Study Liver"},{"issue":"3","key":"3746_CR4","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10555-023-10084-4","volume":"42","author":"Y Wang","year":"2023","unstructured":"Wang Y, Deng B. Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. Cancer Metastasis Rev. 2023;42(3):629\u201352.","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"3746_CR5","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/apt.70427","volume":"63","author":"S Liu","year":"2026","unstructured":"Liu S, Li Z, Lin J, Ke L, Hua Y. Meta-Analysis: Immune-Related Adverse Events Are Associated With Improved Effectiveness of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Aliment Pharmacol Ther. 2026;63(2):188\u2013202.","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"3746_CR6","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1111\/liv.15953","volume":"44","author":"Y Qin","year":"2024","unstructured":"Qin Y, Han S, Yu Y, Qi D, Ran M, Yang M, et al. Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy. Liver international: official J Int Association Study Liver. 2024;44(8):1808\u201331.","journal-title":"Liver international: official J Int Association Study Liver"},{"issue":"6","key":"3746_CR7","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2217\/fon-2020-0327","volume":"17","author":"WJ Xie","year":"2021","unstructured":"Xie WJ, Zhang S, Su L, Li YH, Zhang X, Ran YG. The efficacy and safety of lenvatinib in the treatment of solid tumors: an up-to-date meta-analysis. Future Oncol (London England). 2021;17(6):745\u201354.","journal-title":"Future Oncol (London England)"},{"issue":"1","key":"3746_CR8","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-024-01647-1","volume":"17","author":"Y Chen","year":"2024","unstructured":"Chen Y, Dai S, Cheng CS, Chen L. Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives. J Hematol Oncol. 2024;17(1):130.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"3746_CR9","doi-asserted-by":"publisher","first-page":"104069","DOI":"10.1016\/j.drudis.2024.104069","volume":"29","author":"FM Fan","year":"2024","unstructured":"Fan FM, Fleishman JS, Chen J, Chen ZS, Dong HH. New insights into the mechanism of resistance to lenvatinib and strategies for lenvatinib sensitization in hepatocellular carcinoma. Drug Discovery Today. 2024;29(8):104069.","journal-title":"Drug Discovery Today"},{"issue":"3","key":"3746_CR10","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s10555-022-10071-1","volume":"42","author":"SQ Sin","year":"2023","unstructured":"Sin SQ, Mohan CD, Goh RMW, You M, Nayak SC, Chen L, et al. Hypoxia signaling in hepatocellular carcinoma: Challenges and therapeutic opportunities. Cancer Metastasis Rev. 2023;42(3):741\u201364.","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"3746_CR11","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.apsb.2021.09.019","volume":"12","author":"D Du","year":"2022","unstructured":"Du D, Liu C, Qin M, Zhang X, Xi T, Yuan S, et al. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta Pharm Sinica B. 2022;12(2):558\u201380.","journal-title":"Acta Pharm Sinica B"},{"issue":"4","key":"3746_CR12","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.jhep.2021.12.028","volume":"76","author":"T Cramer","year":"2022","unstructured":"Cramer T, Vaupel P. Severe hypoxia is a typical characteristic of human hepatocellular carcinoma: Scientific fact or fallacy? J Hepatol. 2022;76(4):975\u201380.","journal-title":"J Hepatol"},{"issue":"1","key":"3746_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-019-0720-y","volume":"12","author":"Y Mou","year":"2019","unstructured":"Mou Y, Wang J, Wu J, He D, Zhang C, Duan C, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 2019;12(1):34.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3746_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41392-024-01769-5","volume":"9","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Meng Y, Li D, Yao L, Le J, Liu Y, et al. Ferroptosis in cancer: From molecular mechanisms to therapeutic strategies. Signal Transduct Target therapy. 2024;9(1):55.","journal-title":"Signal Transduct Target therapy"},{"issue":"1","key":"3746_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12943-022-01530-y","volume":"21","author":"C Zhang","year":"2022","unstructured":"Zhang C, Liu X, Jin S, Chen Y, Guo R. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol Cancer. 2022;21(1):47.","journal-title":"Mol Cancer"},{"key":"3746_CR16","doi-asserted-by":"publisher","first-page":"103134","DOI":"10.1016\/j.redox.2024.103134","volume":"72","author":"C Morgenstern","year":"2024","unstructured":"Morgenstern C, Lastres-Becker I, Demird\u00f6\u011fen BC, Costa VM, Daiber A, Foresti R, et al. Biomarkers of NRF2 signalling: Current status and future challenges. Redox Biol. 2024;72:103134.","journal-title":"Redox Biol"},{"issue":"8","key":"3746_CR17","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41419-024-06939-5","volume":"15","author":"X An","year":"2024","unstructured":"An X, Yu W, Liu J, Tang D, Yang L, Chen X. Oxidative cell death in cancer: mechanisms and therapeutic opportunities. Cell Death Dis. 2024;15(8):556.","journal-title":"Cell Death Dis"},{"issue":"11","key":"3746_CR18","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1182\/blood-2011-10-387464","volume":"119","author":"MC Bouton","year":"2012","unstructured":"Bouton MC, Boulaftali Y, Richard B, Arocas V, Michel JB, Jandrot-Perrus M. Emerging role of serpinE2\/protease nexin-1 in hemostasis and vascular biology. Blood. 2012;119(11):2452\u20137.","journal-title":"Blood"},{"issue":"3","key":"3746_CR19","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/cac2.12527","volume":"44","author":"S Zhang","year":"2024","unstructured":"Zhang S, Jia X, Dai H, Zhu X, Song W, Bian S, et al. SERPINE2 promotes liver cancer metastasis by inhibiting c-Cbl-mediated EGFR ubiquitination and degradation. Cancer Commun (London England). 2024;44(3):384\u2013407.","journal-title":"Cancer Commun (London England)"},{"issue":"20","key":"3746_CR20","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1158\/0008-5472.CAN-21-4140","volume":"82","author":"B Hu","year":"2022","unstructured":"Hu B, Zou T, Qin W, Shen X, Su Y, Li J, et al. Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3-ABCB1 Signaling in Hepatocellular Carcinoma. Cancer Res. 2022;82(20):3845\u201357.","journal-title":"Cancer Res"},{"issue":"4","key":"3746_CR21","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1097\/HEP.0000000000000237","volume":"79","author":"AD Ladd","year":"2024","unstructured":"Ladd AD, Duarte S, Sahin I, Zarrinpar A. Mechanisms of drug resistance in HCC. Hepatology (Baltimore MD). 2024;79(4):926\u201340.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"3","key":"3746_CR22","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/cdd.2015.158","volume":"23","author":"Y Xie","year":"2016","unstructured":"Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, et al. Ferroptosis: process and function. Cell Death Differ. 2016;23(3):369\u201379.","journal-title":"Cell Death Differ"},{"issue":"9","key":"3746_CR23","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1080\/15548627.2020.1810918","volume":"17","author":"X Chen","year":"2021","unstructured":"Chen X, Li J, Kang R, Klionsky DJ, Tang D. Ferroptosis: machinery and regulation. Autophagy. 2021;17(9):2054\u201381.","journal-title":"Autophagy"},{"issue":"9","key":"3746_CR24","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.7150\/ijbs.83348","volume":"19","author":"J Li","year":"2023","unstructured":"Li J, Jia YC, Ding YX, Bai J, Cao F, Li F. The crosstalk between ferroptosis and mitochondrial dynamic regulatory networks. Int J Biol Sci. 2023;19(9):2756\u201371.","journal-title":"Int J Biol Sci"},{"issue":"6","key":"3746_CR25","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s00204-023-03476-6","volume":"97","author":"B Wang","year":"2023","unstructured":"Wang B, Wang Y, Zhang J, Hu C, Jiang J, Li Y, et al. ROS-induced lipid peroxidation modulates cell death outcome: mechanisms behind apoptosis, autophagy, and ferroptosis. Arch Toxicol. 2023;97(6):1439\u201351.","journal-title":"Arch Toxicol"},{"issue":"12","key":"3746_CR26","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.tips.2023.08.012","volume":"44","author":"C Scarpellini","year":"2023","unstructured":"Scarpellini C, Klejborowska G, Lanthier C, Hassannia B, Vanden Berghe T, Augustyns K. Beyond ferrostatin-1: a comprehensive review of ferroptosis inhibitors. Trends Pharmacol Sci. 2023;44(12):902\u201316.","journal-title":"Trends Pharmacol Sci"},{"key":"3746_CR27","doi-asserted-by":"publisher","unstructured":"Gelerstein-Claro S, M\u00e9ndez-Vald\u00e9s G, Rodrigo R. Effects of the pharmacological modulation of NRF2 in cancer progression. Med (Kaunas Lithuania). 2025;61(12). https:\/\/doi.org\/10.3390\/medicina61122224.","DOI":"10.3390\/medicina61122224"},{"key":"3746_CR28","doi-asserted-by":"publisher","unstructured":"Ranbhise JS, Singh MK, Ju S, Han S, Yun HR, Kim SS et al. The redox paradox: cancer\u2019s double-edged sword for malignancy and therapy. Antioxid (Basel Switzerland). 2025;14(10). https:\/\/doi.org\/10.3390\/antiox14101187.","DOI":"10.3390\/antiox14101187"},{"issue":"4","key":"3746_CR29","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40262-023-01225-7","volume":"62","author":"TYJ Appeldoorn","year":"2023","unstructured":"Appeldoorn TYJ, Munnink THO, Morsink LM, Hooge MNL, Touw DJ. Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review. Clin Pharmacokinet. 2023;62(4):559\u201371.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"3746_CR30","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/s41419-025-08105-x","volume":"16","author":"D Qi","year":"2025","unstructured":"Qi D, Qin Y, Zhu H, Li Y, Han S. Resistance of first-line targeted drugs in hepatocellular carcinoma: the epigenetic regulation mechanisms. Cell Death Dis. 2025;16(1):875.","journal-title":"Cell Death Dis"},{"issue":"5","key":"3746_CR31","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.7150\/ijbs.107195","volume":"21","author":"R Chen","year":"2025","unstructured":"Chen R, Hu X, Huang Y, Jiang Y, Chen G, Shan Q, et al. Regulated Cell Death in Lenvatinib Resistance of Hepatocellular Carcinoma: from Molecular Mechanisms to Therapeutic Strategies. Int J Biol Sci. 2025;21(5):2012\u201326.","journal-title":"Int J Biol Sci"},{"key":"3746_CR32","doi-asserted-by":"publisher","first-page":"607906","DOI":"10.3389\/fcell.2020.607906","volume":"8","author":"X Zhang","year":"2020","unstructured":"Zhang X, Jiang D, Yang S, Sun Y, Liu Y, Shi J, et al. BAP31 Promotes Tumor Cell Proliferation by Stabilizing SERPINE2 in Hepatocellular Carcinoma. Front cell Dev biology. 2020;8:607906.","journal-title":"Front cell Dev biology"},{"issue":"16","key":"3746_CR33","first-page":"4945","volume":"63","author":"M Buchholz","year":"2003","unstructured":"Buchholz M, Biebl A, Neesse A, Wagner M, Iwamura T, Leder G, et al. SERPINE2 (protease nexin I) promotes extracellular matrix production and local invasion of pancreatic tumors in vivo. Cancer Res. 2003;63(16):4945\u201351.","journal-title":"Cancer Res"},{"key":"3746_CR34","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/1476-4598-9-271","volume":"9","author":"S Bergeron","year":"2010","unstructured":"Bergeron S, Lemieux E, Durand V, Cagnol S, Carrier JC, Lussier JG, et al. The serine protease inhibitor serpinE2 is a novel target of ERK signaling involved in human colorectal tumorigenesis. Mol Cancer. 2010;9:271.","journal-title":"Mol Cancer"},{"key":"3746_CR35","doi-asserted-by":"publisher","first-page":"1585935","DOI":"10.3389\/fonc.2025.1585935","volume":"15","author":"HL Liu","year":"2025","unstructured":"Liu HL, Gao X, Yang W, Li WL. SerpinE2 promotes M2 polarization in macrophage to accelerate colorectal cancer progression. Front Oncol. 2025;15:1585935.","journal-title":"Front Oncol"},{"key":"3746_CR36","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.canlet.2019.11.011","volume":"469","author":"J Zhang","year":"2020","unstructured":"Zhang J, Luo A, Huang F, Gong T, Liu Z. SERPINE2 promotes esophageal squamous cell carcinoma metastasis by activating BMP4. Cancer Lett. 2020;469:390\u20138.","journal-title":"Cancer Lett"},{"key":"3746_CR37","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.canlet.2021.10.001","volume":"524","author":"J Zhang","year":"2022","unstructured":"Zhang J, Wu Q, Zhu L, Xie S, Tu L, Yang Y, et al. SERPINE2\/PN-1 regulates the DNA damage response and radioresistance by activating ATM in lung cancer. Cancer Lett. 2022;524:268\u201383.","journal-title":"Cancer Lett"},{"issue":"4","key":"3746_CR38","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ccell.2024.03.011","volume":"42","author":"G Lei","year":"2024","unstructured":"Lei G, Zhuang L, Gan B. The roles of ferroptosis in cancer: Tumor suppression, tumor microenvironment, and therapeutic interventions. Cancer Cell. 2024;42(4):513\u201334.","journal-title":"Cancer Cell"},{"key":"3746_CR39","volume-title":"Cancer associated fibroblast exosomal miR-214-3p regulated by hnRNPA2B1 promotes cisplatin resistance by inhibiting ferroptosis","author":"W Tian","year":"2025","unstructured":"Tian W, Chen K, Deng L, Ding W, Niu X, Feng F, et al. Cancer associated fibroblast exosomal miR-214-3p regulated by hnRNPA2B1 promotes cisplatin resistance by inhibiting ferroptosis. London, England: International journal of surgery; 2025."},{"issue":"6","key":"3746_CR40","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41419-024-06814-3","volume":"15","author":"O Saatci","year":"2024","unstructured":"Saatci O, Alam R, Huynh-Dam KT, Isik A, Uner M, Belder N, et al. Targeting LINC00152 activates cAMP\/Ca(2+)\/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer. Cell Death Dis. 2024;15(6):418.","journal-title":"Cell Death Dis"},{"issue":"30","key":"3746_CR41","first-page":"e04372","volume":"12","author":"M Guo","year":"2025","unstructured":"Guo M, Chen S, Sun J, Xu R, Qi Z, Li J, et al. PIP5K1A Suppresses Ferroptosis and Induces Sorafenib Resistance by Stabilizing NRF2 in Hepatocellular Carcinoma. Adv Sci (Weinheim Baden-Wurttemberg Germany). 2025;12(30):e04372.","journal-title":"Adv Sci (Weinheim Baden-Wurttemberg Germany)"},{"issue":"8","key":"3746_CR42","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.freeradbiomed.2004.06.011","volume":"37","author":"DA Dickinson","year":"2004","unstructured":"Dickinson DA, Levonen AL, Moellering DR, Arnold EK, Zhang H, Darley-Usmar VM, et al. Human glutamate cysteine ligase gene regulation through the electrophile response element. Free Radic Biol Med. 2004;37(8):1152\u20139.","journal-title":"Free Radic Biol Med"},{"issue":"1\u20132","key":"3746_CR43","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.mam.2008.08.009","volume":"30","author":"CC Franklin","year":"2009","unstructured":"Franklin CC, Backos DS, Mohar I, White CC, Forman HJ, Kavanagh TJ. Structure, function, and post-translational regulation of the catalytic and modifier subunits of glutamate cysteine ligase. Mol Aspects Med. 2009;30(1\u20132):86\u201398.","journal-title":"Mol Aspects Med"},{"key":"3746_CR44","doi-asserted-by":"publisher","unstructured":"Kajarabille N, Latunde-Dada GO. Programmed cell-death by ferroptosis: antioxidants as mitigators. Int J Mol Sci. 2019;20(19). https:\/\/doi.org\/10.3390\/ijms20194968.","DOI":"10.3390\/ijms20194968"},{"issue":"1","key":"3746_CR45","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.cmet.2020.12.007","volume":"33","author":"YP Kang","year":"2021","unstructured":"Kang YP, Mockabee-Macias A, Jiang C, Falzone A, Prieto-Farigua N, Stone E, et al. Non-canonical Glutamate-Cysteine Ligase Activity Protects against Ferroptosis. Cell Metabol. 2021;33(1):174\u2013. \u2013\u200989.e7.","journal-title":"Cell Metabol"},{"issue":"6","key":"3746_CR46","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-025-01145-0","volume":"24","author":"DD Zhang","year":"2025","unstructured":"Zhang DD. Thirty years of NRF2: advances and therapeutic challenges. Nat Rev Drug Discovery. 2025;24(6):421\u201344.","journal-title":"Nat Rev Drug Discovery"},{"issue":"5","key":"3746_CR47","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.bbamcr.2018.02.010","volume":"1865","author":"I Bellezza","year":"2018","unstructured":"Bellezza I, Giambanco I, Minelli A, Donato R. Nrf2-Keap1 signaling in oxidative and reductive stress. Biochim et Biophys acta Mol cell Res. 2018;1865(5):721\u201333.","journal-title":"Biochim et Biophys acta Mol cell Res"},{"issue":"1","key":"3746_CR48","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12974-023-02738-5","volume":"20","author":"Y Li","year":"2023","unstructured":"Li Y, Huang J, Wang J, Xia S, Ran H, Gao L, et al. Human umbilical cord-derived mesenchymal stem cell transplantation supplemented with curcumin improves the outcomes of ischemic stroke via AKT\/GSK-3\u03b2\/\u03b2-TrCP\/Nrf2 axis. J Neuroinflamm. 2023;20(1):49.","journal-title":"J Neuroinflamm"},{"key":"3746_CR49","doi-asserted-by":"publisher","first-page":"103104","DOI":"10.1016\/j.redox.2024.103104","volume":"71","author":"W Huang","year":"2024","unstructured":"Huang W, Wu D, Cai C, Yao H, Tian Z, Yang Y, et al. Inhibition of MST1 ameliorates neuronal apoptosis via GSK3\u03b2\/\u03b2-TrCP\/NRF2 pathway in spinal cord injury accompanied by diabetes. Redox Biol. 2024;71:103104.","journal-title":"Redox Biol"},{"key":"3746_CR50","doi-asserted-by":"publisher","first-page":"101274","DOI":"10.1016\/j.drup.2025.101274","volume":"82","author":"T Yang","year":"2025","unstructured":"Yang T, Zhang S, Nie K, Cheng C, Peng X, Huo J, et al. ZNF207-driven PRDX1 lactylation and NRF2 activation in regorafenib resistance and ferroptosis evasion. Drug Resist updates: reviews commentaries Antimicrob anticancer Chemother. 2025;82:101274.","journal-title":"Drug Resist updates: reviews commentaries Antimicrob anticancer Chemother"},{"issue":"4","key":"3746_CR51","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41401-020-0443-1","volume":"42","author":"CS Ma","year":"2021","unstructured":"Ma CS, Lv QM, Zhang KR, Tang YB, Zhang YF, Shen Y, et al. NRF2-GPX4\/SOD2 axis imparts resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer cells. Acta Pharmacol Sin. 2021;42(4):613\u201323.","journal-title":"Acta Pharmacol Sin"},{"issue":"7","key":"3746_CR52","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41419-022-05044-9","volume":"13","author":"I de Souza","year":"2022","unstructured":"de Souza I, Monteiro LKS, Guedes CB, Silva MM, Andrade-Tomaz M, Contieri B, et al. High levels of NRF2 sensitize temozolomide-resistant glioblastoma cells to ferroptosis via ABCC1\/MRP1 upregulation. Cell Death Dis. 2022;13(7):591.","journal-title":"Cell Death Dis"},{"issue":"23","key":"3746_CR53","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1158\/0008-5472.CAN-22-4001","volume":"83","author":"K Chang","year":"2023","unstructured":"Chang K, Chen Y, Zhang X, Zhang W, Xu N, Zeng B, et al. DPP9 Stabilizes NRF2 to Suppress Ferroptosis and Induce Sorafenib Resistance in Clear Cell Renal Cell Carcinoma. Cancer Res. 2023;83(23):3940\u201355.","journal-title":"Cancer Res"},{"key":"3746_CR54","doi-asserted-by":"publisher","first-page":"107406","DOI":"10.1016\/j.compbiomed.2023.107406","volume":"166","author":"D Zhang","year":"2023","unstructured":"Zhang D, Sun R, Di C, Li L, Zhao F, Han Y, et al. Microdissection of cancer-associated fibroblast infiltration subtypes unveils the secreted SERPINE2 contributing to immunosuppressive microenvironment and immuotherapeutic resistance in gastric cancer: A large-scale study integrating bulk and single-cell transcriptome profiling. Comput Biol Med. 2023;166:107406.","journal-title":"Comput Biol Med"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03746-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03746-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03746-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T02:50:09Z","timestamp":1786416609000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03746-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3746"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03746-y","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"28 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Ethics Committee of the Second Affiliated Hospital of Nanchang University approved the inclusion of human participants and the use of human data and tissues in this study, and conducted them in accordance with the principles of the Declaration of Helsinki. All animal experiments were approved by the Institutional Animal Care and Use Committee of Nanchang Royo Biotech Co. Ltd. (Ethics ID: RYE2025082202).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read and approved submission to this journal.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"174"}}